Peer-reviewed research, clinical commentary, and press on ketamine therapy, addiction psychiatry, and telehealth.
Peer-reviewed publications
Peer-reviewed
At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study
Parks AC, Woodward AL, Henry RD, Arden KA, Vando L, Swain J, Lamichhane B.
Journal of Medical Internet Research
Retrospective evaluation of at-home subcutaneous ketamine in 3,870 patients across 38 states; the study reported feasibility and symptom improvements in depression, anxiety, and PTSD.
At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data
Mathai DS, Hull TD, Vando L, Malgaroli M.
Journal of Affective Disorders
Real-world outcomes from 11,441 patients, with machine-learning and symptom-network analyses of treatment response.
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial
Hull TD, Malgaroli M, Gazzaley A, Akiki TJ, Madan A, Vando L, Arden K, Swain J, Klotz M, Paleos C.
Journal of Affective Disorders
Prospective, open-label effectiveness trial of 1,247 adults receiving at-home sublingual ketamine with telehealth support; the study reported improvements in anxiety and depression and described adverse events.
American Psychiatric Association Annual Meeting — San Francisco
Presented real-world outcomes of at-home, telehealth-supported ketamine treatment: improvement in most patients after four sessions, resolution of suicidal ideation in a majority of those who reported it at baseline, and results comparable to in-clinic IV ketamine. Video interview: Healio Psychiatry, June 27, 2023.
Quoted in coverage of public comments opposing the DEA's proposed telehealth controlled-substance rules, arguing access should be based on medical need, not geography or wealth.
Largest Study of Psychedelic Medicine, With 11,441 Mindbloom Clients, Demonstrates Effectiveness and Safety of Guided At-home Ketamine Therapy
Mindbloom announcement of the 2024 Journal of Affective Disorders study, quoting co-author Dr. Vando. Dr. Vando serves as Mindbloom’s Medical Director.
Medical reviewer of Mindbloom's patient-education library (ketamine safety, ketamine as a psychedelic, the therapeutic process, continuing treatment) and featured researcher on the evidence hub.
Editorial review board, NSCA Personal Training Quarterly
Investigator, industry-sponsored clinical trials in major depressive disorder and tardive dyskinesia (phase 3–4)
Participant, NYS OASAS Opioid Treatment Program Medical Director Collaborative
Training: MD, Ponce School of Medicine (2001); Psychiatry residency (2001–2005) and Addiction Psychiatry fellowship (2005–2006), Beth Israel Medical Center / Icahn School of Medicine at Mount Sinai; BS Chemistry, Sacred Heart University